BG Medicine, Inc. Announces Availability of Galectin-3 Testing Through Cleveland HeartLab, Inc.

BG Medicine, Inc.

BG Medicine, Inc. Announces Availability of Galectin-3 Testing Through Cleveland HeartLab, Inc.

October 27, 2011

WALTHAM, Mass. -- (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel, biomarker-based diagnostics, announced today that Cleveland HeartLab, Inc. is now offering BGM Galectin-3TM testing services.

 "The launch of galectin-3 testing services by Cleveland HeartLab, Inc., a leading specialty clinical reference laboratory, grows the increasing pool of physicians who now have convenient access to this important new test and complements the broad range of cardiovascular tests already being offered to physicians through Cleveland HeartLab, Inc.," said Pieter Muntendam, MD, President and CEO of BG Medicine, Inc.

 "Cleveland HeartLab, Inc. prides itself on being a leader in cardiovascular disease management through the use of a novel, five-biomarker CVD Inflammation ProfileTM that enables physicians to determine if and to what degree their patients are at risk for cardiovascular disease," said Jake Orville, President and CEO of Cleveland HeartLab. "Galectin-3 testing complements our approach to cardiovascular disease management and will assist physicians in making important clinical decisions for their patients. Cleveland HeartLab, Inc. is dedicated to offering cutting-edge testing to physicians in an effort to improve patient management, and the addition of galectin-3 to our test menu supports this mission."

About BG Medicine, Inc.

BG Medicine, Inc. (Nasdaq:BGMD) is a life sciences company focused on the discovery, development, and commercialization of novel, biomarker-based diagnostics to improve patient outcomes and contain healthcare costs. The Company recently launched the BGM Galectin-3TM test for use in patients with heart failure, the first novel blood test for cardiac disease cleared by the U.S. F.D.A. in five years.  BG Medicine also has products in development to aid in the diagnosis and management of acute atherothrombosis and lipid disorders. For additional information about BG Medicine, heart failure and galectin-3 testing, please visit www.bg-medicine.com and www.galectin-3.com.

The BG Medicine Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=10352

About Cleveland HeartLab, Inc.

Cleveland HeartLab, Inc. is a specialty clinical laboratory and disease management company focused on offering a robust menu of propriety diagnostic tests based on unique molecular biomarkers.  Cleveland HeartLab, Inc. operates a CLIA-certified and CAP-accredited clinical reference laboratory, and has developed a profile of tests that physicians use in the management and reduction of inflammation in their patients.  Cleveland HeartLab, Inc. also runs a research & development laboratory where next-generation cardiovascular disease biomarkers are being developed for use by physicians.  This valuable pipeline of tests is part of an exclusive intellectual property portfolio that targets large, under-addressed markets. Several of these tests have been licensed from Cleveland Clinic.  For more information about Cleveland HeartLab, Inc., please visit the company's web site at www.clevelandheartlab.com.

Special Note Regarding Forward-looking Statements

Certain statements made in this news release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "estimate," "anticipate" or other comparable terms.  Forward-looking statements in this news release address our beliefs regarding the importance of galectin-3 testing and our beliefs regarding the expected benefits of our galectin-3 testing services being made available to physicians and patients through Cleveland HeartLab, Inc.  Forward-looking statements are based on management's current expectations and involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our recent filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements.  We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made.  Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

CONTACT:

Michael W. Rogers

EVP & Chief Financial Officer

(781) 890-1199